Redesign Science

Redesign Science is a private, pre-clinical stage biotech company pioneering a dynamic structure-based drug discovery approach. Its core technology, the NUVO™ platform, uniquely integrates enhanced sampling molecular dynamics (physics) with generative AI (chemistry) and machine learning on synthetic data to model protein motion, discover novel binding pockets, and design optimized drug candidates. The company is advancing an internal pipeline of first-in-class small molecules aimed at modulating protein-protein interactions, targeting complex diseases in oncology and autoimmune indications where traditional methods have struggled. Redesign Science operates as a therapeutics company, indicating a focus on developing and commercializing its own drugs rather than providing a pure technology service.

NUVO™ platform integrates proprietary enhanced sampling molecular dynamics (Matisse) to simulate protein dynamics, generative AI (Picasso) for molecule design, and machine learning on synthetic data (Cézanne) for scalable prediction. It aims to discover and design small molecule Targeted Protein Interaction Modulators (TPIM™).

Redesign Science competes in the crowded AI/ML drug discovery space against companies like Schrödinger (public, physics-based), Relay Therapeutics (public, focused on protein motion), and numerous generative AI-focused biotechs. Its differentiation lies in the deep integration of commercialized enhanced sampling MD as the core data generator, rather than relying primarily on historical datasets.